Oncofinder is a Research-Use Only (RUO) platform that is being
developed for the diagnosis, staging and prognosis of melanoma using the
lipid fingerprints acquired from tissue or liquid biopsies. A panel of lipid
biomarkers allows the rapid and accurate screening of benignant nevi from
melanomas by studying the lipid fingerprint using mass spectrometry and
artificial intelligence. This technology circumvents the limitations inherent to current
methodologies, based on dermoscopic, histopathological and surrogate
biomarkers, reducing the laboratory work and providing a faster and easier
diagnosis. Moreover, the specificity of the lipid biomarkers together with the
power of mass spectrometry and machine learning confer to the
Oncofinder platform strong prognostic capabilities not only to detect
melanoma but also to determinate their malignant potential. However, the
high complexity, size and cost of the mass spectrometers limits its
implementation in anatomic pathology analytical services.
In this work, we evaluate a prototype dual polarity linear benchtop MALDITOF
mass spectrometer (Shimadzu) for the generation of the lipid profiles.
A preliminary screening of a collection of human biopsies of nevi and
melanomas demonstrated a high potential for screening melanoma from
benignant biopsies with a sensitivity near 100% with a representative
collection of samples.
- Content Type:
- Document Number:
- ASMS 2020 - WP 399
- Product Type:
- Life Science, MALDI-TOF Mass Spectrometry
- Pharma & Biopharma, Life Science Solutions, MALDI-8020 Benchtop Linear MALDI-TOF Mass Spectrometer
- File Name:
- File Size:
Question about this literature?